Related Experiment Video
Updated: Aug 14, 2026
12:05
Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation
Published on: November 3, 2018
[15 patients with myelodysplastic syndrome]
Vutreshni Bolesti
|January 1, 1989
Summary
This study analyzed 15 myelodysplastic syndrome patients, finding that blast cell counts in bone marrow are crucial for prognosis. Treatment varied, with some patients receiving chemotherapy for refractory anemia with excess blast cells.
Area of Science:
- Hematology
- Oncology
Context:
- Myelodysplastic syndromes (MDS) are a group of clonal hematopoietic stem cell disorders.
- Diagnosis and prognosis of MDS are critical for effective patient management.
- This study reviews cases treated at a Hematologic Clinic over three years.
Purpose:
- To analyze the clinical characteristics, diagnosis, and outcomes of 15 myelodysplastic syndrome patients.
- To evaluate the prognostic significance of blast cell counts in bone marrow.
- To describe treatment strategies for different subtypes of MDS.
Summary:
- Fifteen patients (10 male, 5 female) with myelodysplastic syndrome were classified into refractory anemia (4), acquired idiopathic sideroblast anemia (3), and refractory anemia with excess blast cells (8).
- Diagnosis was confirmed via morphologic, isotopic, and cytogenetic analyses. Seven patients died, with five autopsies confirming progression to acute leukemia.
- Survival ranged from 6 months to 9 years. Patients with refractory anemia with excess blast cells received mercaptopurine or cytosine arabinoside, alongside supportive care.
Impact:
- Highlights the prognostic importance of bone marrow blast cell percentage in myelodysplastic syndrome.
- Provides insights into treatment variations based on MDS subtype and disease progression.
- Contributes to understanding the clinical course and outcomes of myelodysplastic syndromes.
